ScoreWhy is Ipca Laboratories Ltd ?
1
Company has a low Debt to Equity ratio (avg) at 0.04 times
2
Poor long term growth as Operating profit has grown by an annual rate 4.36% of over the last 5 years
3
With a growth in Operating Profit of 27.55%, the company declared Very Positive results in Sep 25
- The company has declared positive results for the last 6 consecutive quarters
- OPERATING CF(Y) Highest at Rs 1,321.32 Cr
- ROCE(HY) Highest at 17.89%
- INVENTORY TURNOVER RATIO(HY) Highest at 3.72 times
4
With ROE of 13.2, it has a Fair valuation with a 4.9 Price to Book Value
- The stock is trading at a discount compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of -1.75%, its profits have risen by 59.6% ; the PEG ratio of the company is 0.6
5
High Institutional Holdings at 47.2%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Ipca Labs should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Ipca Labs for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Ipca Labs
12.94%
-0.05
34.92%
Sensex
-5.11%
0.43
11.83%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
12.22%
EBIT Growth (5y)
3.17%
EBIT to Interest (avg)
39.56
Debt to EBITDA (avg)
0.88
Net Debt to Equity (avg)
-0.05
Sales to Capital Employed (avg)
0.98
Tax Ratio
24.24%
Dividend Payout Ratio
13.76%
Pledged Shares
0
Institutional Holding
48.08%
ROCE (avg)
17.41%
ROE (avg)
11.91%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
33
Industry P/E
34
Price to Book Value
4.86
EV to EBIT
24.85
EV to EBITDA
19.60
EV to Capital Employed
5.05
EV to Sales
4.02
PEG Ratio
0.76
Dividend Yield
0.13%
ROCE (Latest)
20.33%
ROE (Latest)
14.93%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Bullish
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend14What is working for the Company
ROCE(HY)
Highest at 19.55%
CASH AND CASH EQUIVALENTS(HY)
Highest at Rs 564.59 cr
DEBTORS TURNOVER RATIO(HY)
Highest at 4.79 times
PAT(Q)
Highest at Rs 334.12 cr.
0What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Loading Valuation Snapshot...
Here's what is working for Ipca Labs
Profit After Tax (PAT) - Quarterly
Highest at Rs 334.12 cr.
in the last five quartersMOJO Watch
Near term PAT trend is positive
PAT (Rs Cr)
Profit After Tax (PAT) - Quarterly
At Rs 334.12 cr has Grown at 28.1% (vs previous 4Q average)
over average PAT of the previous four quarters of Rs 260.75 CrMOJO Watch
Near term PAT trend is positive
PAT (Rs Cr)
Cash and Cash Equivalents - Half Yearly
Highest at Rs 564.59 cr
in the last six half yearly periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
Debtors Turnover Ratio- Half Yearly
Highest at 4.79 times
in the last five half yearly periodsMOJO Watch
Company has been able to settle its Debtors faster
Debtors Turnover Ratio
Here's what is not working for Ipca Labs
Non Operating Income - Quarterly
Highest at Rs 93.74 cr
in the last five quartersMOJO Watch
Increased income from non business activities may not be sustainable
Non Operating Income
